PDS Biotech refocuses on PDS0301, discontinues PDS0101 Phase 3 trial; Q2 net loss $9.8M

PDS Biotechnology Corp

Q2 2026 net loss $9.8M ($0.18/share) vs $9.4M ($0.21) year-ago; cash $5.6M at June 30.
Strategic refocus: PDS0301 (IL-12 immunocytokine) becomes lead program; PDS0101 VERSATILE-003 Phase 3 trial discontinued.
Positive mCRC data: ORR 77.8% (7/9) with PDS0301 vs 35% (7/20) without; 24-month survival ~80% vs ~35%.
Company to pursue partnerships for PDS0101 development; R&D expenses down to $3.3M from $4.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.